An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer is organized by Clinical Care Options (CCO), LLC and will be held on May 31, 2019 at Sheraton Grand Chicago, Chicago, Illinois, United States of America. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits™.
This program is intended for oncologists and other allied healthcare professionals caring for patients with metastatic breast cancer receiving targeted therapy.
The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians caring for their patients with MBC receiving CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors, and promising investigational agents.
• Evaluate current guidelines and current/emerging clinical trial data on everolimus, palbociclib, palbociclib, and abemaciclib (in addition to others under clinical investigation) to aid in the refinement of current treatment algorithms for patients with de novo or recurrent HR-positive/HER2-negative MBC
• Describe current therapeutic strategies and ongoing clinical trials of targeted therapy–based combinations for both early-stage and HR-positive, HER2-negative MBC
• Identify ongoing trials investigating novel treatment options after disease progression on endocrine and/or CDK4/6 inhibitor-based therapy to aid in clinical trial participation
Additional details will be posted as soon as they are available.
|Contact No. :||1-855-224-2241
Conference Fee Details
|Early Fee Last date||:||NA|